RenovoRx Revenue Surges 136% as Cancer Centers Expand
Event summary
- RenovoRx reported Q1 2026 revenue of $563,000, a 136% increase from Q4 2025.
- Active commercial cancer centers grew to 16, with 32 additional centers in evaluation.
- Phase III TIGeR-PaC trial enrollment expected to complete by June 2026.
- Company ended Q1 with $12.4 million in cash, sufficient for operations into at least the second half of 2027.
- Reiterated full-year 2026 revenue guidance of $3 to $4 million.
The big picture
RenovoRx's strong Q1 2026 performance highlights the growing adoption of its RenovoCath device in cancer centers, driven by increasing procedural utilization and repeat orders. The company's dual-track strategy of commercial expansion and clinical trial advancement positions it to capitalize on the $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with long-term potential in additional solid tumor indications. The completion of the TIGeR-PaC trial and the transition of trial sites to commercial use could further accelerate revenue growth in the second half of 2026.
What we're watching
- Commercial Momentum
- Whether RenovoRx can sustain its rapid expansion of active cancer centers and convert trial sites into commercial use.
- Clinical Trial Outcomes
- The pace at which the TIGeR-PaC trial completes and the potential impact of its results on future regulatory approvals.
- Financial Sustainability
- How the company's current cash reserves will support operations and potential future financing needs.
Related topics